Methadone, naloxone

PreclinicalSmall molecule

KKuopio University Hospital

Methadone, naloxone is one of 4 small molecule programs targeting Methadone. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MethadoneWithdrawn

MethadonePreclinical

Withdrawn

Competition

Competitive Landscape

4 competitors in Methadone

#DrugCompanyPhaseTrials

Isentress

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 2

Oxycontin

PPurdue Pharma LP

Preclinical

1 3

IV Vancomycin

MMelinta Therapeutics, Inc.

Preclinical

1 4

Methadone, naloxone

KKuopio University Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Methadone1 trial

Naloxone Methadone Combination (NAMEKO)

Withdrawn·KKuopio University Hospital·N/A·NCT01160432

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Methadone, naloxone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Methadone, naloxone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Methadone, naloxone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kuopio University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: KKuopio University Hospital

Methadone, naloxone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Methadone1 trial

References

Drug Info

Quick Facts

Related News